Central serous chorioretinopathy due to tadalafil use

Basit Öğe Kaydı
dc.contributor.authorTurkcu, Fatih Mehmet
dc.contributor.authorYuksel, Harun
dc.contributor.authorSahin, Alparslan
dc.contributor.authorMurat, Mehmet
dc.contributor.authorBozkurt, Yasar
dc.contributor.authorCaca, Ihsan
dc.date.accessioned2024-04-24T16:02:11Z
dc.date.available2024-04-24T16:02:11Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractPhosphodiesterase-5 (PDE5) inhibitors are commonly used in the treatment of erectile dysfunction. There are a small number of case reports that associate this agent with central serous chorioretinopathy (CSCR). Our report presents the treatment approach to a 42-year-old patient who described blurred vision and metamorphopsia and was diagnosed with CSCR following the use of tadalafil, a PDE5 inhibitor.en_US
dc.identifier.doi10.1007/s10792-012-9646-x
dc.identifier.endpage180en_US
dc.identifier.issn0165-5701
dc.identifier.issn1573-2630
dc.identifier.issue2en_US
dc.identifier.pmid23065016
dc.identifier.scopus2-s2.0-84879464043
dc.identifier.scopusqualityQ2
dc.identifier.startpage177en_US
dc.identifier.urihttps://doi.org/10.1007/s10792-012-9646-x
dc.identifier.urihttps://hdl.handle.net/11468/14674
dc.identifier.volume33en_US
dc.identifier.wosWOS:000315621000013
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleCentral serous chorioretinopathy due to tadalafil useen_US
dc.titleCentral serous chorioretinopathy due to tadalafil use
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu